Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Salasar Techno Engineering Limited Capital/Financing Update 2026

Feb 14, 2026

60476_rns_2026-02-14_4f08d99a-cec9-4974-acb4-21b75e3c5057.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Salasar Techno Engineering Limited

==> picture [180 x 32] intentionally omitted <==

Date: 14.02.2026

To,

The Manager – Listing The Secretary National Stock Exchange of India Ltd. Exchange Corporate Relationship Dept. Plaza, Bandra Kurla Complex Bandra East BSE Limited Mumbai – 400051 P. J. Tower, Dalal Street, Symbol - SALASAR Mumbai – 400001 Scrip Code: 540642

SUB: Monitoring Agency Report for quarter ended December 31, 2025

Dear Sir/ Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Monitoring Agency Report for the quarter ended 31[st] December 2025, issued by CARE Ratings Limited to monitor the utilization of proceeds of the Preferential Issue of Equity Shares and Fully-Convertible Warrants.

The above information will be made available on the Company’s website at www.salasartechno.com

You are requested to kindly take the same on record.

Yours faithfully,

For Salasar Techno Engineering Limited

MOHIT Digitally signed by KUMAR MOHIT KUMAR GOEL Date: 2026.02.14 GOEL 14:55:32 +05'30'

Mohit Kumar Goel

Company Secretary & Compliance Officer

CIN No. - L23201UP2001PLC209751

==> picture [12 x 18] intentionally omitted <==

==> picture [17 x 17] intentionally omitted <==

Corporate Office: - A-301-320, 3[rd] Floor, Tower-A, Plot No.8, Block-B, Sec-62, Noida U.P 201309

==> picture [16 x 16] intentionally omitted <==

+91 7017538987, 8750725142 +91 9368883592 +91 7417971568

Regd. Off. & Unit 1: - Khasra 265, 281-288, Parsaun-Dasna, Jindal Nagar, Distt. HapurU.P. 201015

Unit 2- Khasra 1184, 1185, Khera, Pilkhuwa, Tehsil Dhaulana, Distt. Hapur, U.P.-245304

Unit 3- Khasra 686/6, Khera, Pilkhuwa, Tehsil Dhaulana, Distt. Hapur, U.P.- 245304 www.salasartechno.com

[email protected] [email protected]

==> picture [137 x 38] intentionally omitted <==

No. CARE/NRO/GEN/2025-26/1207

The Board of Directors

Salasar Techno Engineering Limited

Khasra No. 265,281,282, 283,284,285, 286, 287 and 288 Jindal Nagar, Parsaun Dasna Uttar Pradesh, Hapur, India-201313

February 14, 2026

Dear Sir/Ma’am,

Monitoring Agency Report for the quarter ended December 31, 2025 - in relation to the Preferential Issue of Salasar Techno Engineering Limited (“the Company”)

We write in our capacity of Monitoring Agency (MA) for the preferential Issue for the amount aggregating to Rs. 290.77 crore (Preferential issue of equity share: Rs. 166.67 crores & Preferential issue of share warrants: Rs.124.10 crores) of the Company and refer to our duties cast under 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended December 31, 2025, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated May 01, 2024.

Request you to kindly take the same on records.

Thanking you,

Yours faithfully,

==> picture [114 x 21] intentionally omitted <==

Rajan Sukhija

Associate Director

[email protected]

==> picture [124 x 173] intentionally omitted <==

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

CIN-L67190MH1993PLC071691

==> picture [137 x 37] intentionally omitted <==

Report of the Monitoring Agency

Name of the issuer: Salasar Techno Engineering Limited For quarter ended: December 31, 2025 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: No

  • (b) Range of Deviation: Not Applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board.

==> picture [124 x 173] intentionally omitted <==

==> picture [113 x 21] intentionally omitted <==

Signature:

Name and designation of the Authorized Signatory: Rajan Sukhija Designation of Authorized person/Signing Authority: Associate Director

CARE Ratings Limited

9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

CIN-L67190MH1993PLC071691

==> picture [137 x 37] intentionally omitted <==

1) Issuer Details:

Name of the issuer : Salasar Techno Engineering Limited Name of the promoter : Mr. Alok Kumar Industry/sector to which it belongs : Industrial Products - Iron & Steel Products

2) Issue Details

Issue Period : April 30, 2024, to October 29, 2025 Type of issue (public/rights) : Preferential Issue Type of specified securities : Equity shares and fully convertible warrants IPO Grading, if any : Not applicable Issue size (in crore) : Rs. 290.77 crore

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars Reply Source of information /
certifications considered
by Monitoring Agency for
preparation of report
Comments of the
Monitoring Agency
Comments
of the
Board of
Directors
Whether all utilization is as per the disclosures
in the Offer Document?
No Management Certificate,
Chartered Accountant
certificate*, Bank statements
1.
The company has received only 25% of the issue price from part of the non-
promoter group, i.e., the application money while the promoter group has
bought in the entire 100% of their share of the warrants. The proceeds received
have been utilized in accordance with the objects given as per offer documents.
2.
Non-exercise of warrant by the holders, due to the share price remaining below
the warrant exercise price, leading to the forfeiture of the subscription amount
of 25% of the issue price (i.e., Rs. 11.70 crore) by the company. It has resulted
in ~12% shortfall in fund-raising, hence, the expected timeline for completion
of the object(s) will be impacted.
Note 1
Whether shareholder approval has been
obtained in case of material deviations# from
expenditures disclosed in the Offer Document?
Not
applicable
Not applicable Not applicable No
comments
Whether the means of finance for the
disclosed objects of the issue have changed?
No National Stock Exchange The non-exercise of the warrant conversion option by the holders, due to the share
price remaining below the warrant exercise price, has resulted in a ~12% shortfall
in fundraising. Furthermore, the exercise period for the warrants has lapsed on
October 29, 2025. The company has also not revised the costs of its objects, and
Note 1
CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B,
Noida,
Gautam Budh Nagar, Uttar Pradesh -201301
Phone: +91-120-4452000
4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: [email protected] • www.careedge.in
CIN-L67190MH1993PLC071691

==> picture [137 x 37] intentionally omitted <==

Particulars Reply Source of information /
certifications considered
by Monitoring Agency for
preparation of report
Comments of the
Monitoring Agency
Comments
of the
Board of
Directors
due to shortfall in fund raising, the means of finance of the issue are expected to
change. Further, all the funds raised have been completely utilized during Q3FY26
and hence this would be the last Monitoring report.
Is there any major deviation observed over the
earlier monitoring agency reports?
No Not applicable Not applicable No
comments
Whether all Government/statutory approvals
related to the object(s) have been obtained?
Yes Board Resolution, Offer
Document
1.
Initially, under the EGM dated February 19, 2024, preferential issue of Rs.
806.04 crore was approved. Subsequently, issue size was reduced & the objects
of the issue were modified via board resolution dated April 30, 2024.
2.
Board Resolution dated October 22, 2024, for extension of timeline for issue
related expenses from September 2024 to December 2025.
No
comments
Whether all arrangements pertaining to
technical assistance/collaboration are in
operation?
Not
applicable
Not applicable Not applicable No
comments
Are there any favorable/unfavorable events
affecting the viability of these object(s)?
Yes Bombay Stock Exchange
Website, Board Resolution,
Offer Document
The non-exercise of the warrant conversion option by the holders, due to the share
price remaining below the warrant exercise price, has resulted in a significant
shortfall in fund-raising, ultimately impacting the viability of the stated object(s).
Note 1
Is there any other relevant information that
may materially affect the decision making of
the investors?
Yes Bombay Stock Exchange
Website
1.
The Directorate of Enforcement (ED) has conducted a search operation on April
16, 2025, at the residential premises of Mr. Alok Kumar, Chairman & Managing
Director, & Mr. Shashank Agarwal, Joint Managing Director of the company.
2.
Non-exercise of warrant by part of the non-promoter group, due to the share
price remaining below the warrant exercise price, has resulted in a significant
shortfall in fund-raising, ultimately impacting the viability of the stated
object(s). Board of Directors may take note of the same.
Note 2
Note 1
  • *CA certificate from Prateek Gupta & Co. (peer reviewed) dated January 16, 2026.

Where material deviation may be defined to mean:

a) Deviation in the objects or purposes for which the funds have been raised

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

Note 1: The shortfall in receipt of funds will not affect the viability and competition of the objects because the objects will be achieved from the other means of finance such as internal accruals and external debts.

Note 2: As on date there is no further development in this case and we have updated everything on BSE and NSE exchange.

CARE Ratings Limited

9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

CIN-L67190MH1993PLC071691

==> picture [47 x 21] intentionally omitted <==

==> picture [137 x 37] intentionally omitted <==

4) Details of objects to be monitored:

(i) Cost of objects –

S.
No.
Item
Head
Source of information /
certifications considered by
Monitoring Agency for
preparation of report
Original cost
(as per the
Offer
Document)
in Rs. Crore
Comment Comments of the Board of Directors Comments of the Board of Directors Comments of the Board of Directors
Revised
Cost
in Rs.
Crore
s of the
Monitori
ng
Agency
Reason for
cost
revision
Proposed
financing
option
Particulars of -
firm
arrangements
made
1 Issue related expenses Offer Document, Board Resolution copy 46.04 7.77 *
^
No comments No comments No comments
2 General Corporate Purposes Offer Document, Board Resolution copy 185.00 0.00 No comments No comments No comments
3 Working capital requirements Offer Document, Board Resolution copy 300.00 95.00 No comments No comments No comments
4 Financing of acquisition Offer Document, Board Resolution copy 250.00 178.00 No comments No comments No comments
5 Capital
Expenditure
including
towards
development, refurbishment and renovation of
Assets
Offer Document, Board Resolution copy 25.00 10.00 No comments No comments No comments
Total 806.04 290.77

*Initially company obtained shareholders’ approval for the preferential issue of Rs. 806.04 through EGM dated February 19, 2024. However, subsequently the company made preferential issue of Rs. 290.77 crores only and objects of the issue were revised accordingly as per the above table through board resolution dated April 30, 2024.

^The Issue Period, which spanned 18 months from the date of allotment, concluded on October 29, 2025. During this period, warrants from part of the non-promoter group were not converted into equity shares, as the shares consistently traded below the exercise price. Consequently, subscribers chose not to exercise the warrants. The non-exercise of warrants by the holders has resulted in a significant shortfall in fund-raising, ultimately impacting the viability and means of finance of the stated object(s).

– (ii) Progress in the objects

S.
No
1
Item
Head
Source of
information /
certifications
considered by
Monitoring Agency
for preparation of
report
Amount
as
proposed
in the
Offer
Documen
t in Rs.
Crore
Amount
raised
till date
i.e.
Decemb
er 31,
2025
Amount utilised in Rs. Crore utilised in Rs. Crore Total
unutilis
Comments of
the
Monitoring
Agency
Comments of the
Board of Directors
Comments of the
Board of Directors
As at
beginning of
the quarter
in Rs. Crore
Reasons
for idle
funds
Proposed
course of
action
During At the end ed

the
of the amount
quarter in quarter in in Rs.

Rs. Crore

Rs. Crore
crore
Issue related expenses Management
Certificate, CA
certificate*, Board
7.77 255.67 0.21 0.00 0.21 0.00 No utilization
during
Q3FY26. This
would be the
No
comments
No
comments
CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B,
Noida,
Gautam Budh Nagar, Uttar Pradesh -201301
Phone: +91-120-4452000
4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: [email protected] • www.careedge.in
CIN-L67190MH1993PLC071691

==> picture [137 x 37] intentionally omitted <==

S.
No
Item
Head
Source of
information /
certifications
considered by
Monitoring Agency
for preparation of
report
Amount
as
proposed
in the
Offer
Documen
t in Rs.
Crore
Amount
raised
till date
i.e.
Decemb
er 31,
2025
Amount utilised in Rs. Crore utilised in Rs. Crore Total
unutilis
Comments of
the
Monitoring
Agency
Comments of the
Board of Directors
Comments of the
Board of Directors
As at
beginning of
the quarter
in Rs. Crore
Reasons
for idle
funds
Proposed
course of
action
During At the end ed

the
of the amount
quarter in quarter in in Rs.

Rs. Crore

Rs. Crore
crore
Resolution copy, Bank
statements
last monitoring
report.
2 Working
capital
requirements
Management
Certificate, CA
certificate*, Board
Resolution copy, Bank
statements
95.00 53.29 22.90 76.19 Rs. 22.90
crores are
utilized to
meet its
working capital
requirements.
This would be
the last
monitoring
report.1
No
comments
No
comments
3 Financing of acquisition Management
Certificate, CA
certificate*, Board
Resolution copy, Bank
statements
178.00 179.27^ 0.00 179.27^ No utilization
during
Q3FY26. This
would be the
last monitoring
report.
No
comments
No
comments
4 Capital Expenditure
including towards
development,
refurbishment and
renovation of Assets
Management
Certificate, CA
certificate*, Board
Resolution copy, Bank
statements
10.00 0.00 0.00 0.00 No utilization
during
Q3FY26. This
would be the
last monitoring
report.
No
comments
No
comments
Total 290.77 232.77 22.90 255.67
CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B,
Noida,
Gautam Budh Nagar, Uttar Pradesh -201301
Phone: +91-120-4452000
4th Floor, Godrej Coliseum, Somaiya Hospital
Road, Off Eastern Express Highway, Sion (East),
Mumbai - 400 022
Phone: +91-22-6754 3456
Email: [email protected] • www.careedge.in
CIN-L67190MH1993PLC071691
*CA certificate from Prateek Gupta & Co. (peer reviewed) dated January 16, 2026.
^Utilization is within permission limit of +/- 10%.

==> picture [137 x 37] intentionally omitted <==

1The company had transferred funds from the monitoring account to the current account of Salasar Techno Engineering Limited. However, there were numerous other debits and credits in the current account. Accordingly, we were not clearly able to ascertain the utilization of issue proceeds. We have thus relied on documents submitted by the company, including management certification and CA Certificate confirming the utilization of the proceeds.

(iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds: (iii) Deployment of unutilized proceeds:
Sr.
No.
Type of instrument and name of the entity
invested in
Amount invested (In Rs.
Crore)
Maturity
date
Earning Return on
Investment (%)
Market Value as at the end of
quarter
Nil

– (iv) Delay in implementation of the object(s)

Completion Date Completion Date Comments of the Board of Directors
Delay (no. of
Objects As per the offer
Proposed course of
Actual
days/ months)
Reason of delay

document


action
Issue related expenses December 2025* Ongoing Short receipt of
funds
No further funds required
Not Ascertainable^
Working capital requirements December 2025 Ongoing Short receipt of
funds
Will be managed from
internal accruals and
external debts
Not Ascertainable^
Financing of acquisition December 2025 June 2024 No Delay No comments No comments
Capital Expenditure including towards development, refurbishment and renovation of
Assets
October 2025 Delayed Not Ascertainable^ Short receipt of
funds
Will be managed from
internal accruals

*Board of Directors vide board resolution dated October 22, 2024, has extended the timeline for utilization of issue related expenses to December 2025 through board resolution as against earlier timeline of September 2024.

^The Issue Period, which spanned 18 months from the date of allotment, concluded on October 29, 2025. During Q3FY26, no warrants from the non-promoter group were converted into equity shares, as the shares consistently traded below the exercise price. Consequently, subscribers chose not to exercise the warrants. Non-exercise of warrant by the holders, due to the share price remaining below the warrant exercise price, has resulted in a significant shortfall in fund-raising, hence, the expected timelines for completion of the object(s) will be impacted. Further, this significant shortfall in fund-raising, also impacting the viability and means of finance of the stated object(s).

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

==> picture [47 x 21] intentionally omitted <==

CIN-L67190MH1993PLC071691

==> picture [137 x 37] intentionally omitted <==

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. Item Amount (in Rs. Source of information / certifications considered by Monitoring Agency for Comments of Monitoring Comments of the Board of
No Head
Crore)

preparation of report

Agency
Directors
Not Applicable*
  • *CA certificate from Prateek Gupta & Co. (peer reviewed) dated January 16, 2026.

CARE Ratings Limited

9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

CIN-L67190MH1993PLC071691

==> picture [47 x 21] intentionally omitted <==

==> picture [123 x 173] intentionally omitted <==

==> picture [137 x 37] intentionally omitted <==

Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as “Monitoring Agency/MA” ). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditor (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from statutory auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

==> picture [124 x 172] intentionally omitted <==

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: [email protected] • www.careedge.in

CIN-L67190MH1993PLC071691